Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average – Here’s What Happened

by · The Cerbat Gem

Shares of Compugen Ltd. (NASDAQ:CGEN – Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.58 and traded as high as $1.60. Compugen shares last traded at $1.56, with a volume of 132,777 shares changing hands.

Wall Street Analysts Forecast Growth

CGEN has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Compugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.00.

Read Our Latest Report on CGEN

Compugen Price Performance

The firm has a market cap of $139.21 million, a PE ratio of -7.09 and a beta of 2.59. The business’s 50 day moving average price is $1.68 and its 200 day moving average price is $1.58.

Compugen (NASDAQ:CGEN – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Compugen had a negative net margin of 87.45% and a negative return on equity of 34.77%. The firm had revenue of $1.89 million for the quarter, compared to analyst estimates of $1.47 million. As a group, analysts predict that Compugen Ltd. will post -0.03 earnings per share for the current year.

Institutional Trading of Compugen

Several large investors have recently made changes to their positions in CGEN. US Bancorp DE purchased a new position in Compugen in the 1st quarter valued at $29,000. Franklin Resources Inc. purchased a new stake in shares of Compugen during the second quarter worth $56,000. R Squared Ltd acquired a new stake in shares of Compugen in the second quarter valued at about $71,000. Osaic Holdings Inc. lifted its stake in shares of Compugen by 346.0% in the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after buying an additional 34,045 shares in the last quarter. Finally, Schnieders Capital Management LLC purchased a new position in shares of Compugen in the first quarter worth about $131,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

Compugen Company Profile

(Get Free Report)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Further Reading